MovDisordV3, PubMed, Curation, bibRecord, 001701

Calcium channel blocker use and risk of Parkinson's disease.

Identifieur interne : 001701 ( PubMed/Curation ); précédent : 001700; suivant : 001702

Calcium channel blocker use and risk of Parkinson's disease.

Auteurs : Kelly Claire Simon [États-Unis] ; Xiang Gao ; Honglei Chen ; Michael A. Schwarzschild ; Alberto Ascherio

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.

RBID : pubmed:20669249

English descriptors

KwdEn :
- Calcium Channel Blockers (therapeutic use), Female, Humans, Hypertension (drug therapy), Male, Nurses, Parkinson Disease (etiology), Proportional Hazards Models, Risk.
MESH :
- chemical , therapeutic use : Calcium Channel Blockers.
- drug therapy : Hypertension.
- etiology : Parkinson Disease.
- Female, Humans, Male, Nurses, Proportional Hazards Models, Risk.

Abstract

We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.

DOI: 10.1002/mds.23191
PubMed: 20669249

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001701

Links to Exploration step

pubmed:20669249

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcium channel blocker use and risk of Parkinson's disease.</title>
<author><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name>
</author>
<author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
</author>
<author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A" last="Schwarzschild">Michael A. Schwarzschild</name>
</author>
<author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.23191</idno>
<idno type="RBID">pubmed:20669249</idno>
<idno type="pmid">20669249</idno>
<idno type="wicri:Area/PubMed/Corpus">001701</idno>
<idno type="wicri:Area/PubMed/Curation">001701</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Calcium channel blocker use and risk of Parkinson's disease.</title>
<author><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name>
</author>
<author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name>
</author>
<author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A" last="Schwarzschild">Michael A. Schwarzschild</name>
</author>
<author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calcium Channel Blockers (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypertension (drug therapy)</term>
<term>Male</term>
<term>Nurses</term>
<term>Parkinson Disease (etiology)</term>
<term>Proportional Hazards Models</term>
<term>Risk</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Nurses</term>
<term>Proportional Hazards Models</term>
<term>Risk</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20669249</PMID>
<DateCreated><Year>2010</Year>
<Month>09</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>12</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>08</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>12</Issue>
<PubDate><Year>2010</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Calcium channel blocker use and risk of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>1818-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23191</ELocationID>
<Abstract><AbstractText>We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.</AbstractText>
<CopyrightInformation>© 2010 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon</LastName>
<ForeName>Kelly Claire</ForeName>
<Initials>KC</Initials>
<AffiliationInfo><Affiliation>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Honglei</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schwarzschild</LastName>
<ForeName>Michael A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ascherio</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 NS048517</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 NS048517</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 NS048517-05</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2001 Jul;50(1):56-63</RefSource>
<PMID Version="1">11456310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2007 Jun 28;447(7148):1081-6</RefSource>
<PMID Version="1">17558391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1991 Feb 15;541(2):342-6</RefSource>
<PMID Version="1">1647250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 1997;50:79-88</RefSource>
<PMID Version="1">9120427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1997 Mar;68(3):1221-33</RefSource>
<PMID Version="1">9048769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Feb 10;72(6):578-9</RefSource>
<PMID Version="1">19204275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aging Cell. 2007 Jun;6(3):337-50</RefSource>
<PMID Version="1">17328689</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neural Transm. 2004 Aug;111(8):1031-40</RefSource>
<PMID Version="1">15254791</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2007 Oct;6(10):933-8</RefSource>
<PMID Version="1">17884683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 15;70(16 Pt 2):1438-44</RefSource>
<PMID Version="1">18256367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Apr;13(3):165-9</RefSource>
<PMID Version="1">17055323</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009726">Nurses</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS195921</OtherID>
<OtherID Source="NLM">PMC2939261</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.23191</ArticleId>
<ArticleId IdType="pubmed">20669249</ArticleId>
<ArticleId IdType="pmc">PMC2939261</ArticleId>
<ArticleId IdType="mid">NIHMS195921</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001701 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001701 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:20669249
   |texte=   Calcium channel blocker use and risk of Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:20669249" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Calcium channel blocker use and risk of Parkinson's disease.

Calcium channel blocker use and risk of Parkinson's disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki